Results 251 to 260 of about 3,144,476 (264)
Some of the next articles are maybe not open access.
Role of Dicer in regulating oxaliplatin resistance of colon cancer cells
Biochemical and Biophysical Research Communications, 2018Colorectal cancer (CRC) is a major health problem due to its high mortality rate. The incidence of CRC is increasing in young individuals. Oxaliplatin (OXA) is an approved third-generation drug and is used for first-line chemotherapy in CRC. Although current standard chemotherapy improves the overall survival of CRC patients, an increasing number of ...
Hui-Huang Lai +3 more
openaire +2 more sources
Abstract 4559: SMAD3 mediates oxaliplatin resistance in esophageal adenocarcinoma
Cancer ResearchAbstract Background: Resistance to conventional treatments is a significant barrier to esophageal adenocarcinoma (EAC) therapy. TGF-β signaling appears to be important for EAC tumorigenesis; however, its role in EAC chemoresistance remains understudied.
Farah Ballout +8 more
openaire +1 more source
TGFB1-mediated autophagy facilitates oxaliplatin resistance in stomach adenocarcinoma
Biochemistry and Cell BiologyIncreasing evidence has indicated that transforming growth factor beta 1 (TGFB1) is engaged in tumorigenesis and progression. Nevertheless, the underlying role and mechanism of TGFB1 in stomach adenocarcinoma (STAD) chemotherapy remains unknown. TGFB1 levels in various types of cancers were first analyzed by the TCGA database.
Qihua Xu +7 more
openaire +1 more source
Cetuximab sensitivity associated with oxaliplatin resistance in colorectal cancer.
Anticancer research, 2012Clinical studies have suggested that the epidermal growth factor receptor (EGFR)-inhibiting antibody cetuximab may have better effect in the third-line treatment of metastatic colorectal cancer, after failure of standard chemotherapy including oxaliplatin, compared to using it up-front in the first line. The reason behind this suggestion is unclear.The
Lars, Ekblad, Anders, Johnsson
openaire +1 more source